

NeuroMetrix Showcases Quell® Technology at the North Carolina Foot & Ankle Society's Winter Scientific Seminar

The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that <u>Quell</u> Wearable Pain Relief Technology will be featured at the North Carolina Foot & Ankle Society's Winter Scientific Seminar to be held January 28-31 in Greensboro, NC.

"Podiatrists see patients every day who are suffering from chronic pain including nerve pain," says Frank McGillin, Senior Vice President and General Manager, Consumer. "Quell is a new 100% drug free technology that addresses a variety of chronic pain conditions. Patients can wear it 24/7 so they can continue to get therapy while they are sleeping. We see podiatrists as key partners in helping more people with chronic pain to try Quell."

About Quell

Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. It is available for purchase at <u>QuellRelief.com</u>, selected retailers and healthcare professionals.

About NeuroMetrix

NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit <u>www.NeuroMetrix.com</u>.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005971/en/

NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media